Dupilumab: An Opportunity to Unravel In Vivo Actions of IL-4 and IL-13 in Humans

Lennart M Roesner; Charlie Bridgewood; Dennis McGonagle; Miriam Wittmann

doi:10.1016/j.jid.2021.02.007

Dupilumab: An Opportunity to Unravel In Vivo Actions of IL-4 and IL-13 in Humans

J Invest Dermatol. 2021 Aug;141(8):1879-1881. doi: 10.1016/j.jid.2021.02.007.

Authors

Lennart M Roesner¹, Charlie Bridgewood², Dennis McGonagle³, Miriam Wittmann⁴

Affiliations

¹ Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, Germany.
² Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom.
³ Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom; National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), The Leeds Teaching Hospitals, Leeds, United Kingdom.
⁴ Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom; National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), The Leeds Teaching Hospitals, Leeds, United Kingdom. Electronic address: M.Wittmann@leeds.ac.uk.

PMID: 34303467
DOI: 10.1016/j.jid.2021.02.007

Abstract

The application of biologics in clinical practice allows immunological observations under real-life conditions. In a new article in the Journal of Investigative Dermatology, Bakker et al. (2021) use deep immune cell phenotyping to demonstrate how dupilumab acts in a targeted fashion on skin-homing T cells, the driver cells of atopic dermatitis.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Humans
Interleukin-13*
Interleukin-4*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Interleukin-13
Interleukin-4
dupilumab